Scar formation occurs during the late stages of the inflammatory response but, when excessive, produces fibrosis that can lead to functional and structural damage of tissues. Here, we show that the profibrogenic agonist, transforming growth factor ␤1, transcriptionally decreases expression of Exchange protein activated by cAMP 1 (Epac1) in fibroblasts/fibroblast-like cells from multiple tissues (i.e., cardiac, lung, and skin fibroblasts and hepatic stellate cells). Overexpression of Epac1 inhibits transforming growth factor ␤1-induced collagen synthesis, indicating that a decrease of Epac1 expression appears to be necessary for the fibrogenic phenotype, an idea supported by evidence that Epac1 expression in cardiac fibroblasts is inhibited after myocardial infarction. Epac and protein kinase A, a second mediator of cAMP action, have opposite effects on migration but both inhibit synthesis of collagen and DNA by fibroblasts. Epac is preferentially activated by low concentrations of cAMP and stimulates migration via the small G protein Rap1 but inhibits collagen synthesis in a Rap1-independent manner. The regulation of Epac expression and activation thus appear to be critical for the integration of pro-and anti-fibrotic signals and for the regulation of fibroblast function.
exchange protein activated by cyclic AMP ͉ fibrosis ͉ protein kinase A ͉ tissue remodeling T issue fibrosis in the late stages of inflammation leads to organ damage and loss of function but is largely untreatable (1) . Fibrosis results from the conversion of resting fibroblasts to profibrogenic myofibroblasts in response to certain growth factors, e.g., transforming growth factor (TGF) ␤1, and hormones, such as angiotensin II and endothelin (2) .
The cAMP pathway is a potential target to blunt fibrosis: Increases in cAMP levels can decrease fibroblast function after cell injury and inhibit fibroblast-to-myofibroblast conversion (3), which accompanies repair after injury, including ischemic death (e.g., myocardial infarction) (2) . The action of cAMP in eukaryotic cells was thought to occur exclusively via activation of protein kinase A (PKA) and PKA-mediated changes in protein expression and function (4, 5) , but Epac, a guanine nucleotide exchange protein that regulates the activity of the G proteins Rap1 and Rap2, also mediates responses to cAMP (6) (7) (8) (9) . Epac has been implicated in a variety of cellular responses, including proliferation, differentiation, secretion, polarization and ion transport (6, 7, 10, 11) . However, neither the regulation of Epac expression nor the contribution of Epac to pathophysiological processes is well defined.
In the heart, fibroblasts and extracellular matrix derived therefrom form a framework upon which cardiac myocytes contract and the conversion of fibroblasts to myofibroblasts is an important event in repair after myocardial infarction and other injuries (2, 12) . Intracellular cAMP levels evoke numerous cellular responses after cardiac injury (13, 14) . The role of Epac in cardiac injury and repair is not known, although Epac activation can influence other aspects of cardiac function (15) . Here, we show that profibrotic agents inhibit Epac expression and that Epac plays a key role in the integration of pro-and anti-fibrotic responses.
Results
Profibrogenic Agonists Attenuate Epac1 Expression. Two forms of Epac (Epac1 and Epac2) have been identified in a variety of cell types (8); passage 1 cardiac fibroblasts more abundantly express Epac1 than Epac2 (Fig. 1A) . The fibrogenic agonist TGF␤1 promotes conversion of resting fibroblasts to profibrotic myofibroblasts (3), prominently decreasing expression of Epac1 (but not Epac2) mRNA and protein ( Fig. 1 B-D and F) and not that of PKA catalytic subunits ␣ and ␤ mRNA (data not shown). Incubation with TGF␤1 negates an increase in Rap1 activity promoted by Me-cAMP [8-(4-chlorophenylthio)-2Ј-O-methyl-cAMP, an Epacselective agonist] (Fig. 1E) . The G protein-coupled receptor (GPCR) agonist angiotensin II also inhibits Epac1 mRNA expression (Fig. 1G ). Actinomycin D, TGF␤1 and angiotensin II produce similar rates of decay in Epac1 mRNA expression, implicating inhibition of transcription, and not enhanced RNA degradation, in TGF␤1-and angiotensin II-promoted decrease in Epac1 mRNA (Fig. 1 F and G) . TGF␤1 decreases Epac1 mRNA expression in multiple types of fibroblasts: rat cardiac, lung, and skin fibroblasts; mouse hepatic stellate cells; and a human hepatic stellate cell line ( Fig. 1 H-K) . Thus, inhibition of expression of Epac1 occurs in responses to profibrotic activation of fibroblasts from multiple tissues and represents a type of cross-talk between tyrosine kinase receptors (e.g., TGF␤1) and GPCR signaling via cAMP. Our subsequent experiments focused on cardiac fibroblasts. Fig. S1 ] and negated TGF␤1-promoted enhancement of collagen type I␣1, I␣2, and III␣1 mRNA expression (Fig. 2 A-C) . Because mRNA expression of collagens type I␣1 and III␣1 was not changed in cells treated with Epac1-targeted siRNA under conditions that selectively silenced Epac1 (data not shown), decrease of Epac1 expression is necessary, but not sufficient, for generation of the TGF␤1-promoted cardiac fibrotic phenotype. (7, 16) revealed that Epac activation promotes (by 2-to 3-fold), but PKA activation inhibits (by Ϸ50%) fibroblast migration ( Fig. 2D and Fig. S2 A) . Immunocytochemistry indicated that, akin to the observations in ref. 17 , PKA activation (Phe-cAMP) rapidly (within 1 h) produces long branching processes that yield a stellate pattern, whereas Epac activation (Me-cAMP) results in rounded cells without such processes (Fig. 2E) . Epac1 is primarily cytoplasmic under resting conditions but localizes to perinuclear and nuclear regions after activation by Me-cAMP (Fig. 2E) .
We assessed the role of Rap1, a downstream target of Epac (8, 9), on Epac-promoted migration of fibroblasts. Epac activation by Me-cAMP increased GTP-bound (activated) Rap1; PKA activation by Phe-cAMP had negligible effects on such binding (Fig. 2F) . Silencing by Rap1-targeted siRNA (Fig. 2G ) negated Me-cAMPinduced fibroblast migration (Fig. 2H) . Pretreatment with TGF␤1 and angiotensin II inhibited Me-cAMP-induced migration (Fig.  2I) , consistent with their ability to decrease Epac1 expression (Fig.  1) . Thus, Epac activation promotes fibroblast migration via Rap1, whereas activation of PKA inhibits such migration.
Low Concentrations of cAMP Promote Fibroblast Migration, Whereas
Higher cAMP Concentrations Inhibit Such Migration. Several cAMPelevating agents, including stimulants of cAMP synthesis [e.g., adrenomedullin, beraprost (an IP receptor agonist), isoproterenol (a ␤-adrenergic receptor agonist), and the diterpene forskolin) ( Me-cAMP (50 M) and migration was assayed. n ϭ 4 -6; * , P Ͻ 0.05. (I) Migration was examined in cardiac fibroblasts treated with Me-cAMP (50 M) alone, or together with TGF␤1 (10 ng/ml) or angiotensin II (100 nM). n ϭ 4 -7, *** , P Ͻ 0.001.
Both Epac and PKA Activation Inhibit Collagen Type I and III Expression
and DNA Synthesis. Despite their differing effects on fibroblast migration, Me-cAMP and Phe-cAMP both inhibit collagen I␣1, I␣2, and III␣1 mRNA expression (Fig. 4 A-C) and DNA synthesis (Fig. 4D) . Incubation with Rap1-targeted siRNA did not affect Me-cAMP-induced inhibition of collagen and DNA synthesis ( The enhanced synthesis of cAMP by adenylyl cyclase activation stimulates Epac and PKA. Epac promotes fibroblast migration, whereas PKA inhibits migration and fibroblast-to-myofibroblast transformation. Both Epac and PKA inhibit collagen synthesis and fibroblast proliferation. Profibrotic stimuli inhibit Epac expression and stimulate collagen synthesis.
expressed in the area of infarction (Fig. 5A Upper Right) ; TGF ␤1-expressing cells had less Epac1 (green) expression than did TGF ␤1-negative cells. ␣SMA (red) was expressed in the area of infarction and in vessels in sham-operated animals; Epac1 expression was decreased in ␣SMA-expressing cells (Fig. 5B) . Fibroblasts isolated from the intraventricular septa 1 week after myocardial infarction had decreased Epac1 mRNA and protein expression (Fig. 5 C and  D) . We also found decreased expression of Epac1 and high levels of TGF␤1 in the border zone of mice with myocardial infarction (Fig. S4) . Thus, a decrease in Epac1 expression parallels the increase in expression of TGF ␤1 after myocardial infarction, results consistent with those we observed with isolated fibroblasts (Fig. 1 ).
Discussion
The current findings indicate that profibrotic agonists inhibit Epac1 expression in fibroblasts from multiple tissues and that overexpression of Epac1 inhibits TGF␤1-induced collagen synthesis, implying that a decrease in Epac expression is required for profibrotic response. Moreover, PKA and Epac, the two major effectors of cAMP action, differentially regulate fibroblast migration and morphology: Epac promotes migration via Rap1 and expression of a rounded morphology, whereas PKA inhibits migration, decreases fibrogenicity, and produces a stellate appearance. Findings obtained with cAMP derivatives that selectively activate Epac or PKA and with cAMP-elevating agonists indicate that lower cAMP concentrations preferentially promote migration via Epac. Activation of Epac or PKA has opposite effects on fibroblast migration, but both cAMP effectors inhibit collagen and DNA synthesis. Our results, which show that TGF␤1 decreases Epac1 expression in fibroblasts from multiple tissues, are akin to data indicating a similar decrease in Epac1 mRNA expression in U937 monocytic cells (18) : TGF␤-mediated inhibition of Epac expression may thus be a widespread mechanism for controlling responses to mitogens. Smad3 is required for TGF␤-induced gene expression in fibroblasts (19) ; its loss prevents interstitial fibrosis in the heart and attenuates cardiac remodeling (20) , suggesting a role for Smad3 in the decrease of Epac1 by TGF␤. Epac1 protein can interact with type I TGF␤ receptor and inhibit transcriptional activation and phosphorylation of Smad2 (21) . Functionally, the decrease in Epac expression would facilitate localization of fibroblasts at sites where fibrogenesis is required and contribute to this process by blunting the negative impact of Epac activation on collagen synthesis. The ability of overexpression of Epac to block profibrotic response (Fig. 2) suggests that such an approach has the therapeutic potential to inhibit or perhaps reverse tissue fibrosis.
Epac-promoted fibroblast migration appears to occur via Rap1, although PKA may also phosphorylate and regulate Rap1 (22, 23) . The Epac target Rap1-RAPL, a Rap1-binding molecule, can move to a cell's leading edge and activate integrins to promote cell polarization and migration (24) . Our data regarding localization of Epac1 are consistent with evidence that Epac1 localizes perinuclearly in migrating cells, suggesting that Epac1 activates Rap1 in the location where activated Rap1 may associate with RAPL (24) . Perhaps the ability of cAMP-elevating agonists to regulate cell migration to varying degrees results from increases in cAMP that activate compartmentalized PKA isoforms and Epac (25) . By contrast with our data, in fibroblasts, Epac activation inhibits migration of endothelial cells (26) , implying that Epac activation has cell type-differences in its effect on migration.
Our data (Fig. 3) implicate Epac as the preferential effector (vs. PKA) in fibroblast migration in response to increases in cAMP. Previous studies have reached inconsistent conclusions regarding which effector is preferentially involved in cAMP actions (7, 27, 28) . The physiologically relevant cAMP affinities for Epac vs. PKA have not been clearly defined, in part because of limitations in the assays currently available and the difficulty in knowing the contribution of other cellular proteins and constituents to Epac activity in intact cells.
Plasma and tissue levels of cAMP-elevating agonists, including catecholamines and adrenomedullin, rapidly increase in many organs, including the heart, after injury (13) . TGF␤1 expression increases at wound sites 1-3 days after myocardial infarction (29) . Our data indicate that TGF␤1 inhibits fibroblast migration via inhibition of Epac expression and suggest a mechanism for facilitation of TGF␤1 action by promotion of the synthesis of extracellular matrix at sites of injury (3, 29) (Fig. 5E ). This idea is consistent with our in vivo data showing that TGF␤1 is increased and Epac1 expression is decreased in the border zone after myocardial infarction. The ability of TGF␤1 to inhibit expression of Epac1 provides an example of cross-talk between tyrosine kinase receptors and GPCR that occurs at a more distal site in the GPCR signaling pathway that is different than previously noted (30) .
In conclusion, the current data show that inhibition of Epac expression and action contributes to responses induced by profibrotic agents and that increases in intracellular cAMP concentrations (produced by activators of adenylyl cyclase or inhibitors of PDE) preferentially promote migration of fibroblasts via the EpacRap1 pathway. Decreased fibroblast migration in response to profibrotic agents occurs via inhibition of Epac1 expression; prevention of this decrease in Epac expression can inhibit profibrotic response. Because Epac appears to integrate pro-and anti-fibrotic signals, treatments that enhance Epac expression have the potential to blunt and perhaps reverse tissue fibrosis.
Materials and Methods
Antibodies and Regents. Forskolin, adrenomedullin, isoproterenol, TGF␤1, and antibody to ␣-smooth muscle actin were purchased from Sigma. 8-(4-chlorophenylthio)-2Ј-O-methyladenosine-3Ј,5Ј-cyclic monophosphate, 8-pCPT-2Ј-O-Me-cAMP, (Me-cAMP), N 6 -phenyladenosine-3Ј,5Ј-cyclic monophosphate (Phe-cAMP), and 8-(4-chlorophenylthio)-2Ј-O-methyl-cAMPS Sp-isomer (Sp-MecAMP) were purchased from the BIOLOG Life Science Institute. The PKA inhibitor (5-22) (Wiptide) and beraprost were purchased from Anaspec and Cayman Chemical, respectively. Antibodies to Epac1 and Epac2 were purchased from Santa Cruz Biotechnology. Antibody to TGF␤1 was purchased from R&D Systems.
Isolation and Culture of Adult Rat Cardiac, Lung, and Skin Fibroblasts. Cardiac fibroblasts were isolated from adult Sprague-Dawley rats (250 -300 g, male) and cultured as described in ref. 3 . To obtain lung and skin fibroblasts, lung and skin were isolated from anesthetized/heparinized adult Sprague-Dawley rats (250 -300 g, male). Isolated tissues were placed in Ca 2ϩ -and Mg 2ϩ -free PBS, rinsed, minced, and placed into a 60-mm dish and allowed (10 min) to adhere to the dish. Tissue explants were then incubated in medium (DMEM supplemented with 10% FBS, 5% NCS, L-glutamine, sodium pyruvate, and antibiotic-antimycotic), and allowed to incubate in a humidified 5% CO 2-95% atmospheric air incubator at 37°C. Tissue fragments were removed by aspiration; fibroblasts were washed twice with Ca 2ϩ -and Mg 2ϩ -free PBS, trypsinized, and passaged once over a 5-day period. All animals were cared for in compliance with the guiding principles of the American Physiologic Society and as approved by the UCSD Institutional Animal Care and Use Committee. Adenovirus Construction. Full-length cDNA-encoding human Epac1 (kindly provided by J. L. Bos) was cloned into a shuttle vector by using an AdenoX adenovirus construction kit (Clontech) kindly provided by Y. Ishikawa (Yokohama City University, Yokohama, Japan). A control adenovirus vector with GFP was used at the same multiplicity of infection. All experiments were performed 24 h after infection.
Quantitative RT-PCR. Total RNA was isolated by using TRIzol (Invitrogen) according to the manufacturer's instructions. Generation of cDNA and RT-PCR analysis were done as described in ref. 33 . Primers for PCR amplification were designed based on the nucleotide sequences of Epac1; Epac2; collagen I␣1, I ␣2, III ␣1; and GAPDH. Each forward and reverse primer set was designed between multiple exons, and PCR products were confirmed by sequencing (the information of
